These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 17510307)

  • 1. Profiling the antibody immune response against blood stage malaria vaccine candidates.
    Gray JC; Corran PH; Mangia E; Gaunt MW; Li Q; Tetteh KK; Polley SD; Conway DJ; Holder AA; Bacarese-Hamilton T; Riley EM; Crisanti A
    Clin Chem; 2007 Jul; 53(7):1244-53. PubMed ID: 17510307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness.
    Stanisic DI; Richards JS; McCallum FJ; Michon P; King CL; Schoepflin S; Gilson PR; Murphy VJ; Anders RF; Mueller I; Beeson JG
    Infect Immun; 2009 Mar; 77(3):1165-74. PubMed ID: 19139189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of the profiles of IgG subclass-specific responses to Plasmodium falciparum apical membrane antigen-1 and merozoite surface protein-1 in naturally exposed individuals living in malaria hypoendemic settings, Iran.
    Rouhani M; Zakeri S; Mehrizi AA; Djadid ND
    Malar J; 2015 Feb; 14():58. PubMed ID: 25652589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural antibody responses to Plasmodium falciparum MSP3 and GLURP(R0) antigens are associated with low parasite densities in malaria patients living in the Central Region of Ghana.
    Amoah LE; Nuvor SV; Obboh EK; Acquah FK; Asare K; Singh SK; Boampong JN; Theisen M; Williamson KC
    Parasit Vectors; 2017 Aug; 10(1):395. PubMed ID: 28835262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya.
    Polley SD; Conway DJ; Cavanagh DR; McBride JS; Lowe BS; Williams TN; Mwangi TW; Marsh K
    Vaccine; 2006 May; 24(19):4233-46. PubMed ID: 16111789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limited antigenic diversity of Plasmodium falciparum apical membrane antigen 1 supports the development of effective multi-allele vaccines.
    Terheggen U; Drew DR; Hodder AN; Cross NJ; Mugyenyi CK; Barry AE; Anders RF; Dutta S; Osier FH; Elliott SR; Senn N; Stanisic DI; Marsh K; Siba PM; Mueller I; Richards JS; Beeson JG
    BMC Med; 2014 Oct; 12():183. PubMed ID: 25319190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody levels to multiple malaria vaccine candidate antigens in relation to clinical malaria episodes in children in the Kasena-Nankana district of Northern Ghana.
    Dodoo D; Atuguba F; Bosomprah S; Ansah NA; Ansah P; Lamptey H; Egyir B; Oduro AR; Gyan B; Hodgson A; Koram KA
    Malar J; 2011 May; 10():108. PubMed ID: 21529376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human leukocyte antigen class II alleles influence levels of antibodies to the Plasmodium falciparum asexual-stage apical membrane antigen 1 but not to merozoite surface antigen 2 and merozoite surface protein 1.
    Johnson AH; Leke RG; Mendell NR; Shon D; Suh YJ; Bomba-Nkolo D; Tchinda V; Kouontchou S; Thuita LW; van der Wel AM; Thomas A; Stowers A; Saul A; Zhou A; Taylor DW; Quakyi IA
    Infect Immun; 2004 May; 72(5):2762-71. PubMed ID: 15102786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.
    Singh S; Miura K; Zhou H; Muratova O; Keegan B; Miles A; Martin LB; Saul AJ; Miller LH; Long CA
    Infect Immun; 2006 Aug; 74(8):4573-80. PubMed ID: 16861644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein.
    Soe S; Theisen M; Roussilhon C; Aye KS; Druilhe P
    Infect Immun; 2004 Jan; 72(1):247-52. PubMed ID: 14688102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoglobulin G antibodies to merozoite surface antigens are associated with recovery from chloroquine-resistant Plasmodium falciparum in Gambian children.
    Pinder M; Sutherland CJ; Sisay-Joof F; Ismaili J; McCall MB; Ord R; Hallett R; Holder AA; Milligan P
    Infect Immun; 2006 May; 74(5):2887-93. PubMed ID: 16622227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of merozoite surface protein 1 and apical membrane antigen 1 vaccine efficacies against Plasmodium chabaudi malaria based on prechallenge antibody responses.
    Lynch MM; Cernetich-Ott A; Weidanz WP; Burns JM
    Clin Vaccine Immunol; 2009 Mar; 16(3):293-302. PubMed ID: 19116303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New antigens for a multicomponent blood-stage malaria vaccine.
    Osier FH; Mackinnon MJ; Crosnier C; Fegan G; Kamuyu G; Wanaguru M; Ogada E; McDade B; Rayner JC; Wright GJ; Marsh K
    Sci Transl Med; 2014 Jul; 6(247):247ra102. PubMed ID: 25080477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasmodium falciparum merozoite surface antigen-specific cytophilic IgG and control of malaria infection in a Beninese birth cohort.
    Adamou R; Dechavanne C; Sadissou I; d'Almeida T; Bouraima A; Sonon P; Amoussa R; Cottrell G; Le Port A; Theisen M; Remarque EJ; Longacre S; Moutairou K; Massougbodji A; Luty AJF; Nuel G; Migot-Nabias F; Sanni A; Garcia A; Milet J; Courtin D
    Malar J; 2019 Jun; 18(1):194. PubMed ID: 31185998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection.
    Elias SC; Collins KA; Halstead FD; Choudhary P; Bliss CM; Ewer KJ; Sheehy SH; Duncan CJ; Biswas S; Hill AV; Draper SJ
    J Immunol; 2013 Feb; 190(3):1135-47. PubMed ID: 23293353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection.
    Polley SD; Tetteh KK; Lloyd JM; Akpogheneta OJ; Greenwood BM; Bojang KA; Conway DJ
    J Infect Dis; 2007 Jan; 195(2):279-87. PubMed ID: 17191173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral immune response to Plasmodium falciparum vaccine candidate GMZ2 and its components in populations naturally exposed to seasonal malaria in Ethiopia.
    Mamo H; Esen M; Ajua A; Theisen M; Mordmüller B; Petros B
    Malar J; 2013 Feb; 12():51. PubMed ID: 23383869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of HLA-DRB1 alleles on antibody responses to PfCP-2.9-immunized and naturally infected individuals.
    Zhang Q; Xue X; Xu X; Wang C; Chang W; Pan W
    J Clin Immunol; 2009 Jul; 29(4):454-60. PubMed ID: 19247821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-clinical assessment of novel multivalent MSP3 malaria vaccine constructs.
    Bang G; Prieur E; Roussilhon C; Druilhe P
    PLoS One; 2011; 6(12):e28165. PubMed ID: 22145028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.